-transparent.png){kind=logo}
Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX). Patients were randomized to receive HEX alone or combined with prophylactic pyridoxine. There was a 2% response rate in 89 partially or fully evaluable patients. Seven percent of these patients developed neurologic toxicity which occurred in the HEX-alone group only.
Related Publications
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
July 1982,
Cancer treatment reports,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1981,
Cancer treatment reports,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1994,
Cancer investigation,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1983,
Investigational new drugs,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1994,
Investigational new drugs,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
February 1990,
Investigational new drugs,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1983,
Investigational new drugs,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
February 1993,
Anti-cancer drugs,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1997,
Investigational new drugs,
C J Fabian, and
S Rasmussen, and
R Stephens, and
A Haut, and
F Smith, and
S Balcerzak, and
B Tranum
January 1996,
Investigational new drugs,
